Abstracts tagged "Inflammation"

Abstract Number: 1564 • ACR Convergence 2021
Nailfold Capillaroscopy Characterization in COVID-19: A Case Control Study
Paola Estefania Bermudez Bermejo¹, RODOLFO JIMENEZ-SOTO¹, Alain Sanchez-Rodríguez¹, Alonso Turrent¹, Daniela Mercado- Velasco¹, Ian Bravo-Lee¹, Mariana Berenice Colli-Cortés², Everardo Alvarez Hernandez³ and MaryCarmen Amigo¹, ¹CENTRO MEDICO ABC, Mexico City, Mexico, ²Hospital Regional "General Ignacio Zaragoza" ISSSTE, Mexico City, Mexico, ³HOSPITAL GENERAL DE MEXICO, Mexico City, Mexico
Background/Purpose: Nailfold capillaroscopy is a relatively easy-to-access, low-cost clinical tool that could help identify early coagulopathy in subjects with SARS-CoV-2, but specific findings vs. controls…
Abstract Number: 0190 • ACR Convergence 2021
Long-term Safety of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes – Interim Analysis of the RELIANCE Registry
Jasmin Kuemmerle-Deschner¹, Jorg Henes², Birgit Kortus-Goetze³, Tilmann Kallinich⁴, Prasad T. Oommen⁵, Juergen Rech⁶, Frank Weller-Heinemann⁷, Gerd Horneff⁸, Ivan Foeldvari⁹, Aleš Janda¹⁰, Catharina Schuetz¹¹, Frank Dressler¹², Michael Borte¹³, Markus Hufnagel¹⁴, Axel Braner¹⁵, Florian Meier¹⁶, Michael Fiene¹⁷, Julia Weber-Arden¹⁸ and Norbert Blank¹⁹, ¹Pediatric Rheumatology and Autoinflammatory Reference Center, University Children's Hospital Tuebingen, Tuebingen, Germany, ²University Hospital Tuebingen, Tuebingen, Germany, ³Division of Nephrology, University of Marburg, Marburg, Germany, ⁴Charité University Medicine, Nuremberg, Germany, ⁵Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ⁶Friedrich-Alexander University (FAU) Erlangen-Nuernberg and Universitaetsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Germany, Erlangen, Germany, ⁷Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, ⁸Paediatric Rheumatology International Trials Organisation (PRINTO), Sankt Augustin, Germany, ⁹Hamburger Zentrum fuer Kinder- und Jugendrheumatologie, Hamburg, Germany, ¹⁰Department of Pediatrics, University Hospital Ulm, Ulm, Germany, ¹¹Pediatrics, Medizinische Fakultaet Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany, ¹²Division of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany, ¹³ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Leipzig, Germany, ¹⁴Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Hospital Medical Center Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany, ¹⁵Department of Medicine II, Rheumatology, University Hospital Frankfurt, Germany, Frankfurt a.M., Germany, ¹⁶1 Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany 2 Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt am Main, Germany, Frankfurt a.M., Germany, ¹⁷Department of Internal Medicine, District Hospital Demmin, Demmin, Germany, ¹⁸Novartis Pharma GmbH, Nuremberg, Germany, ¹⁹Rheumatology, University Hospital Heidelberg, Eppelheim, Germany
Background/Purpose: Autoinflammatory periodic fever syndromes (PFS) are characterized by severe systemic and organ inflammation. In clinical trials, successful treatment was achieved with the interleukin-1β inhibitor…
Abstract Number: 0728 • ACR Convergence 2021
Intra-articular Canakinumab (anti-interleukin-1β) for Treatment of Symptomatic Knee Osteoarthritis: A Randomized, Double-blind, Placebo and Naproxen-controlled Phase II Study
Philip Conaghan¹, Xavier Chevalier², Linda Mindeholm³, Ursula Schramm³, Jens Praestgaard³, Abdelkader Seroutou³, Ronenn Roubenoff³ and Matthias Schieker³, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Henri Mondor University Hospital and Paris University XII, UPEC, Créteil, France, Créteil, France, ³Novartis Institutes for Biomedical Research, Basel, Switzerland, Basel, Switzerland
Background/Purpose: Knee osteoarthritis (OA) is a common musculoskeletal disease associated with pain and functional impairment. There are few effective therapies, often limited by side-effects.1 This…
Abstract Number: 1114 • ACR Convergence 2021
Pachymeningitis: The Mayo Clinic Experience
Emily Gilbert¹, Mina Al-Awqati², Tina Gunderson³ and Florentina Berianu¹, ¹Mayo Clinic, Jacksonville, FL, ²University of Illinois, Chicago, IL, ³Mayo Clinic, Rochester, MN
Background/Purpose: Pachymeningitis is a rare disorder defined by localized or generalized inflammatory thickening of the dura. It can be associated with infections, malignancy, autoimmune disorders,…
Abstract Number: 1565 • ACR Convergence 2021
Causal Mediation Analysis of the Relationship of Canakinumab’s Protective Effect Against Gout Flares and High-sensitivity C-reactive Protein in the CANTOS Trial
Kazuki Yoshida¹, Robert J. Glynn¹, Hyon K. Choi², Brendan M. Everett¹, Yi Li³, Jean G. MacFadyen¹, Paul M. Ridker¹ and DH Solomon¹, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Lexington, MA, ³Harvard T.H. Chan School of Public Health, Boston, MA
Background/Purpose: Previous analyses in the CANTOS trial demonstrated a benefit of canakinumab (CAN; IL-1β inhibitor) on gout flares. We aimed to quantify the mediating role…
Abstract Number: 0230 • ACR Convergence 2021
Fatigue and Inflammation in Rheumatoid Arthritis Are Already Disconnected Before Clinical Arthritis Develops
Sarah J.H. Khidir¹, Annette H.M van der Helm-van Mil¹ and Elise van Mulligen², ¹Leiden University Medical Center, Leiden, Netherlands, ²Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Fatigue is disabling and common in Rheumatoid Arthritis (RA); the causation of fatigue in RA is multidimensional and only partially explained by inflammation. The…
Abstract Number: 0732 • ACR Convergence 2021
Topical Rofecoxib for OA of the Knee
Bruce Register¹, Nancy Lane², Lee Simon³, John Newsam⁴, Edward Kisak⁴, Jed Pheneger⁵, John Galvin⁵, Jeffrey Klein⁶ and Marc Hochberg⁷, ¹BriOri BioTech, Inc., Newport Beach, CA, ²University of California Davis, Hillsborough, CA, ³SDG LLC, West Newton, MA, ⁴Tioga Research, Inc, San Diego, CA, ⁵Inotiv, Boulder, CO, ⁶Sinclair Research Center, Auxvasse, MO, Canada, ⁷University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Osteoarthritis remains a highly prevalent disease in the elderly, and there are currently no approved treatments that can modify the disease course. Currently, both…
Abstract Number: 1125 • ACR Convergence 2021
Synovial Perivascular Edema Is Associated with Altered Knee Loading Patterns During Gait in Patients with Medial Compartment-Dominant Knee Osteoarthritis
McKenzie Carter¹, Holly Philpott¹, Trevor Birmingham², Ryan Pinto³, Codie Primeau¹, J. Robert Giffin¹, Brent Lanting² and Tom Appleton², ¹Western University, London, ON, Canada, ²University of Western Ontario, London, ON, Canada, ³Western University, Kitchener, ON, Canada
Background/Purpose: Synovial inflammation and aberrant joint loads are independent risk factors for knee osteoarthritis (OA) incidence and progression. Perivascular edema, the accumulation of fluid around…
Abstract Number: 1571 • ACR Convergence 2021
Elevated Lactate, Procalcitonin Levels and SIRS (Systemic Inflammatory Response Syndrome) in a Subset of Patients with Gout
Christopher Podgorski¹, Paula Skarda² and Elie Gertner³, ¹Department of Medicine, University of Minnesota Medical School, Saint Paul, MN, ²Department of Medicine, Regions Hospital, University of Minnesota Medical School, Saint Paul, MN, ³Section of Rheumatology, Regions Hospital and Division of Rheumatology, University of Minnesota Medical School, Minneapolis, MN
Background/Purpose: The intense inflammatory cascade of acute gouty inflammation makes it difficult to differentiate clinically between acute gouty inflammation and sepsis, particularly since they can…
Abstract Number: 0268 • ACR Convergence 2021
Effect of Biologic Agents on Lipids and Cardiovascular Risk in Rheumatoid Arthritis Patients
Dimitrios Pappas¹, George Reed², Kevin Kane², Jeffrey Curtis³ and Joel Kremer⁴, ¹Columbia University, New York, NY, ²University of Massachusetts, Worcester, MA, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Albany Medical College, Latham, NY
Background/Purpose: Cardiovascular disease (CVD) risk scores incorporating measures of inflammation such as the Reynolds risk score (RRS) may be appropriate to predict CVD risk in…
Abstract Number: 0867 • ACR Convergence 2021
A Proteomic/Transcriptomic Analysis Associates with Subclinical Vascular Disease in Systemic Lupus Erythematosus
Christopher Oliveira¹, Yenealem Temesgen-Oyelakin², Mohammad Naqi³, Nidhi Patel², Philip Parel², Massimo Gadina⁴, Stefania Dell'Orso², Stephen Brooks², Sarthak Gupta⁵, Nehal Mehta⁶, Sarfaraz Hasni³ and Mariana Kaplan³, ¹National Institutes of Health (NIH), Vienna, VA, ²National Institutes of Health (NIH), Bethesda, MD, ³National Institutes of Health, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁵National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁶NHLBI/National Institutes of Health, Bethesda, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with enhanced cardiovascular (CV) risk linked to both traditional Framingham risk factors and lupus-specific immune dysregulation. Characterizing an…
Abstract Number: 1126 • ACR Convergence 2021
Synovial Cell Dysfunction in Obese Patients May Contribute to Poor Outcomes in Knee Osteoarthritis
Holly Philpott¹, Trevor Birmingham², Nicole Aye², Benoit Fiset³, Logan Walsh³, Brent Lanting² and Tom Appleton², ¹Western University, London, ON, Canada, ²University of Western Ontario, London, ON, Canada, ³McGill University, Montréal, QC, Canada
Background/Purpose: Obesity is a major risk factor for poor outcomes in knee osteoarthritis (OA) and may involve both mechanical and physiological stresses on joint tissues.…
Abstract Number: 1578 • ACR Convergence 2021
NLRP3 Inflammasome Pathway Expression at Atheroma Plaques from Peripheral Artery Disease According to the Uricemic Status
MARIANO ANDRES¹, Leticia Mendieta², Elena Argente-delcastillo¹, Miguel Trigueros³ and Alberto Miñano³, ¹Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain, ²Universidad Miguel Hernández, San Juan de Alicante, Spain, ³Hospital General Universitario de Alicante-ISABIAL, Alicante
Background/Purpose: Both hyperuricemia and monosodium urate crystals induce persistent inflammation. In vitro, soluble urate can prime innate immune cells and promote NLRP3 inflammasome activation and…
Abstract Number: 0274 • ACR Convergence 2021
Angiopoietin-Like Protein 4, Apolipoprotein C3 and Lipoprotein Lipase Axis in the Abnormal Lipid Profile of Patients with Rheumatoid Arthritis: Relation to Subclinical Atheromatosis
juan Carlos Quevedo¹, Laura de Armás-Rillo², Antonia de Vera-González³, Laura Cáceres¹, Cristina Almeida¹, Alejandra González-Delgado³ and Iván Ferraz-Amaro³, ¹Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain, ²Universidad Europea de Canarias, Santa Cruz De Tenerife, Spain, ³Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increase in cardiovascular (CV) risk, attributed, among other factors, to the existence of an abnormal lipid profile.…
Abstract Number: 0916 • ACR Convergence 2021
Disease Activity and Inflammation in Axial Spondyloarthritis Patients Who Did Not Experience Flares Following Certolizumab Pegol Withdrawal, Dose Reduction or Dose Continuation
Lianne Gensler¹, Xenofon Baraliakos², Lars Bauer³, Bengt Hoepken³, Thomas Kumke³, Mindy Kim⁴ and Robert Landewé⁵, ¹Department of Rheumatology, University of California San Francisco, San Francisco, CA, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ³UCB Pharma, Monheim am Rhein, Germany, ⁴UCB Pharma, Smyrna, GA, ⁵Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands
Background/Purpose: C-OPTIMISE was a phase 3b study investigating certolizumab pegol (CZP) maintenance dose continuation, reduction or withdrawal following achievement of sustained remission in patients with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].